All Updates

All Updates

icon
Filter
Partnerships
AmoyDx partners with Servier to provide companion diagnostic solutions for diffuse glioma in China
Precision Medicine
Jun 26, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 26, 2024

AmoyDx partners with Servier to provide companion diagnostic solutions for diffuse glioma in China

Partnerships

  • Amoy Diagnostics (AmoyDx) has entered a strategic partnership with Servier to co-develop a companion diagnostic (CDx) test for detecting isocitrate dehydrogenase (IDH) 1 and 2 gene mutations.

  • ​​The partnership aims to develop a diagnostic tool for identifying IDH gene mutations, which will be used in the research for a novel drug, "vorasidenib." This drug is designed to inhibit these mutations and is expected to be used to treat Diffuse Lower Grade Glioma patients who carry these mutations in China. AmoyDx will use its Next-Generation Sequencing (NGS) technology for this development and support the drug's registration and commercialization in mainland China. 

  • China-based Amoy Diagnostics specializes in molecular diagnostics for oncology precision medicine. The company offers a range of diagnostic products, including PCR, NGS, FISH, and IHC assays, under proprietary brands such as ADx-ARMS, Super-ARMS, and ADx-HANDLE. AmoyDx also operates the Xiamen Amoy Medical Laboratory and the Shanghai Xiawei Medical Laboratory, which provide third-party clinical inspection services.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.